Abstract. The fusion gene BCR/ABL arises in connection with a complex translocation event in 2-10% of cases with chronic myeloid leukemia (CML). Due to causative treatment with Imatinib most cases with variant rearrangements show no specific prognostic significance, though the events of therapy resistance remain to be studied. Herein we report on three CML cases with complex chromosomal aberrations not observed before, involving chromosomal regions such as 1p32, 2q11 and 6q12. Additionally we report on one case with the rare translocation t(3;8)(p22;q22) along with the classic Philadelphia (Ph) chromosome. In two cases, two different breakpoints on chromosome 22 were found. Moreover, in one of them two breakpoints on chromosome 9 were observed. The following chromosomal studies, during therapy by Imatinib, have revealed different cytogenetic responses.
Introduction
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease which arises following the BCR and ABL somatic gene rearrangement in a pluripotent bone-marrow stem cell. In 90-95% cases with CML, the BCR/ABL fusion gene is the result of reciprocal translocation between chromosomes 9 and 22 and is cytogenetically observable as a small derivative chromosome 22 which is known as Philadelphia (Ph) chromosome (1) .
In a Ph-positive CML expression of the BCR/ABL chimeric protein p210 with an increased tyrosine kinase activity is essential for multiple signaling pathways to confer the leukemia phenotype (2) . Imatinib mesylate (Glivec, formerly STI571) was designed specifically to inhibit the tyrosine kinase activity of the bcr/abl protein and other tyrosine kinases such as c-abl, c-kit and platelet-derived growth factor receptor. By binding to an active site of the tyrosine kinase, Glivec switches off downstream signaling, cells stop proliferating and apoptosis ensues (3) . Many studies have shown a high efficiency of Imatinib therapy to achieve a complete or major cytogenetic response (MCR), i.e. 0-34% Ph-positive cells. This positive effect may be achieved in cases with simple t (9;22) , and complex translocations resulting in a BCR/ABL fusion gene, as well as in cases with cytogenetic clonal evolution (4, 5) .
Complex chromosomal rearrangements involving one or more additional chromosomes were described in >600 cases with CML (6) . By conventional cytogenetic analysis, two variant subgroups have traditionally been recognized: complex, t(9;22;V), where V represents a third translocation partner chromosome and simple, t(9;V) or t(22;V) (7) . Only in a few cases is a chromosomal fragment from the third chromosome translocated to the der(22)t(9;22), producing a 'masked Ph' (8) . In most Ph-variant cases the segment 22q11-qter is moved to a third chromosome, while a part of the third chromosome is located on 9q34. Deletions on the derivative chromosome 9 were found to occur with a much higher frequency in patients with variant Ph translocations (45%) than in those with classic Ph (17%) (9) .
Herein we report on three CML cases with new complex aberrations with three or more chromosomal breakpoints which include 1p32, 2q11 and 6q12. Additionally, a case with a classic Ph chromosome accompanied by a rare translocation (3;8)(p22;q22) was characterized by molecular cytogenetics.
Materials and methods

Case 1.
A 28-year-old male patient presented with leukocytosis. The physical examination showed splenomegaly and hepatomegaly. Blood analysis revealed the hemoglobin concentration at 9.3 g/l, the white blood count (WBC) at 204x10 9 /l, with blasts of 3% and thrombocytosis. 
Results
Case 1.
The presence of abnormal chromosomes 1 and 22, and a possible aberration on chromosome 9 was revealed by GTG-analysis (Fig. 1A) . By applying WCP for chromosomes 1, 9 and 22 a rearrangement between chromosome 1 and 22 was obvious, while chromosome 9 was apparently normal (Fig. 1B) . Using an LSI BCR/ABL ES probe the CML-typical fusion gene was found on the derivative chromosome 22 and was present in 100% of the nuclei (Fig. 1D) . Breakpoints of the chromosomes involved in the rearrangements were verified by MCB (Fig. 1C ) and BAC clones (RP11-808D16, RP11-45F22, RP11-775G6 and RP11-259P1). Thus, three derivative chromosomes were described (Table I) . After a course of hydroxyurea the patient received 400 mg/m 2 Imatinib, daily. MCR was achieved within one year of Imatinib therapy (25% Ph + cells) (Fig. 5) .
Case 2. The first three cytogenetic analyses failed and only interphase FISH using LSI BCR/ABL ES was performed. In the initial sample, 75% of the nuclei exhibited a BCR/ABL fusion gene. This rate remained the same during treatment with Imatinib (60-70% of BCR/ABL positive cells, Fig. 5 ).
The fourth FISH analysis detected the BCR/ABL fusion gene in 100% nuclei and GTG-banding revealed a complex Ph rearrangement involving chromosome 6 ( Fig. 2A) . The BCR/ ABL gene was identified on der (22) (Fig. 2B ). FISH analysis using MCB and BAC clones RP11-387L5 for 6q12 precisely characterized the chromosomal aberration as a t(6;9;22) (q12;q34;q11) ( Fig. 2C-E) . In addition to this presumably primary complex translocation event, secondary chromosomal aberrations were found. By using M-FISH, a trisomy 8 and an isochromosome 17q10 were verified (Fig. 2F) . After a course of hydroxyurea the patient received 400 mg/m 2 Imatinib, but has shown resistance to the treatment (short hematological and minor cytogenetic response (60% Ph + cells within 19 months). The bone marrow was studied briefly 4 times: the first at initial diagnosis, and again after 13, 19 and 28 months (Fig. 5) . The patient succumbed 30 months after diagnosis.
Case 3.
A primary interphase FISH analysis showed the presence of a BCR/ABL fusion gene in 100% of the nuclei. The chromosome quality was not sufficient for GTG-banding. After chemotherapy with hydroxyurea, followed by Imatinib, a secondary cytogenetic study was performed. The BCR/ABL fusion gene was proven in only 44% of the cells. Using GTGbanding two aberrant chromosomes were identified whose origin was discovered by the WCP probes of chromosomes 2 and 22 (Fig. 3A) . Two cell clones with different variants of 
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the rearrangement were characterized. In the first clone 22q11.1->qter was located on chromosome 2, while chromosome 9 was not included in the rearrangement (Fig. 3C ). In the second clone, on chromosome 22 two breaks occurred as a result of which the chromosomal region 22q11.1->q11.2 was translocated on the derivative chromosome 2 and the fragment 22q11.2->qter was detectable on der (9) (Fig. 3D) . The application of LSI BCR/ABL has shown the CML-typical fusion gene on the der(2) in the second clone (Fig. 3B) . After a course of hydroxyurea the patient received 400 mg/m 2 Imatinib, daily. The follow-up cytogenetic studies have shown a decrease in the number of nuclei with BCR/ABL (Fig. 5) . 
is apparently normal (arrows). (B) The fusion gene BCR/ABL (ES LSI BCR/ABL) is located on der(2). (C-D)
Using WCP for chromosomes 2 (green) and 22 (red) two cell clones were found. In one clone the fragment of chromosome 22q11.1->22qter is located on chromosome 2 (red arrow), while chromosome 9 is not included in the rearrangement (C). In the second clone the chromosomal region 22q11.1->q11.2 is transferred on the derivative chromosome 2 (red arrow), as the fragment 22q11.2->22qter is on der(9) (green arrow in D). Case 4. In this case GTG-banding revealed a classical Ph chromosome and a deletion or translocation of the short arm of chromosome 3. The BCR/ABL fusion gene was found in 100% of the nuclei and metaphases. Using the WCP probes of chromosomes 3 and 8 we verified a translocation. The chromosomal break-points were characterized by MCB probes (Fig. 4A and B) . After a course of hydroxyurea the patient received 400 mg/m 2 Imatinib, daily. MCR was achieved within one year (31% Ph + cells) and the follow-up study showed only 10% Ph + cells after 6 months (Fig. 5) .
Discussion
According to the literature, in 2-10% CML cases the fusion gene BCR/ABL is a result of a complex translocation. At present it appears that variant translocations can affect any chromosome. However, it has been suggested that distribution of the break-points is non-random with the chromosomal bands most susceptible to breakage being: 1p36, 3p21, 5q31, 6p21, 9q22, 10q22, 11q13, 12p13, 17p13, 17q21, 17q25, 19q13, 21q22, 22q12 and 22q13 (6) . In our study we revealed three cases with CML with complex translocations, involving different chromosomes. These cases were BCR/ABL positive. In one case the BCR/ ABL fusion gene was located on the derivative chromosome 2, while in others localization was on der (22) . As breakpoints of the third chromosome we identified 1p32, 2q11 and 6q12. The breakpoint 6q12 was not previously described in CML but 1p32 and 2q11 have been mentioned in the catalogue of chromosome aberrations in cancer 2 and 3 times, respectively, in CML (12) .
Two possible mechanisms for variant translocation formation were suggested. The first is a single-event rearrangement via the simultaneous breakage of several chromosomes followed by mismatched joining (13). Nacheva et al proposed a classical Ph translocation followed by a further translocation event between chromosomes 9 and 22 plus a third chromosome (14) . The mechanism of the formation of a variant Ph translocation may have prognostic importance in that a two-event mechanism represents clonal evolution, whereas a variant translocation occurring via a single genomic rearrangement may confer a similar prognosis to the classical Ph translocation (15) .
Two of our cases have demonstrated a two-way mechanism of the formation of the variant translocation. During the first cytogenetic diagnosis in case 3 with a t(2;22;9;22), BCR/ABL fusion gene was observed in 100% nuclei by interphase FISH, while the second cytogenetic investigation after the course of Imatinib therapy revealed the presence of two clones: i) a Phchromosome negative clone with t(2;22)(q11.2?;q11) and ii) with a complex translocation with the BCR/ABL gene on der (2) . Notably, t(2;22) was apparently a primary chromosomal change, and probably, BCR/ABL was a result of the translocation between der(2)t(2;22) and chromosome 9. To the best of our knowledge the chromosomal breakpoint 2q11 has already been described in complex aberrations with 9 and 22. However, two breakpoint events on chromosome 22 were not found previously in the formation of t(2;9;22) (16) (17) (18) .
In case 1 the translocation (9;22) appears to be the first chromosomal event. Further rearrangement developed with a new breakpoint on the der(9), der(22) and on chromosome 1. Cytogenetic studies after Imatinib therapy revealed cells without any chromosomal aberrations. The chromosomal region 1p32.2 has yet to be described as a partner in a complex translocation in CML.
The variant Ph translocation involving chromosome 6 was described in case 2. As the complex aberration was detected in the later phase of the disease, the significance of the rearrangement could not be determined. The patient has also shown complex karyotype with trisomy 8 and isochromosome 17q. Additional chromosomal aberrations are thought to result in a higher genome instability of tumor cells. Trisomy 8 is one of the most frequent aneuploidies in CML patients. According to the literature +8 has no prognostic significance in CML patients (19) . Isochromosome (17)(q10) is one of the non-random changes occurring in CML progression. This aberration is associated with the loss of the tumor suppressor gene TP53 and mostly with poor prognosis (6) . In addition, the monitoring of responses to Imatinib has revealed that CML cases with i(17q) had lower rates of complete or major cytogenetic responses. Notably, the presence of trisomy 8 was associated with a relatively high cytogenetic response rate (5) . To explain the cytogenetic resistance to Imatinib Ph + cases with CML with secondary genetic abnormalities Mohamed et al suggested that the Ph + leukemic cells no longer depend on BCR/ABL for survival (20) .
In case 4 we found a translocation of chromosomes 3 and 8 along the classical Ph. Only CML-associated features were detected in the patient. Breakages of the long arm of chromosome 3 during the clonal evolution of CML were well described in previous literature while the region 3p22 has been known to be a partner of chromosomal rearrangements mostly in solid tumors (12) . Killary et al defined a tumor suppressor locus within the human chromosome 3p21-22 using a rapid functional assay system (21) . The aberrations including the second chromosomal region 8q22 have been found in different neoplastic malignancies as well as in acute myeloid leukemia M2 (22) and the myelodysplastic syndrome ONCOLOGY REPORTS 20: 99-104, 2008 Figure 5 . The monitoring of the presence of fusion gene BCR/ABL in Imatinib therapy patients with CML occurred as reported herein by interphase FISH using an ES LSI BCR/ABL probe. In case 1, the repeated analyses were performed 6 times, in case 2 three times, in cases 3 and 4 four times each. (23) . After the therapy course in Ph-negative cells this aberration was still present. Due to different circumstances the investigation of other tissues has not been performed to define the origin of the translocation. The observation made by Hild and Fonatsch suggested that chromosomal abnormalities observed in addition to the Ph chromosome at the time of the initial diagnosis may not be associated with poor prognosis (24) . A constitutional aberration could also not be ruled out in these cases.
The monitoring of BCR/ABL by interphase FISH during Imatinib treatment has shown a major cytogenetic response in three cases, except that of t(6;9;22). In this study it was not possible to make a significant prognosis of the complex cytogenetic events. However, based on our results, we conclude that patients with variant Ph translocations and a translocation (3;8) without clonal evolution respond well to Imatinib therapy. In summary, our study demonstrates that applying the LSI-probes, M-FISH and MCB allow to comprehensively characterize complex chromosomal rearrangements that were not identified by banding cytogenetics alone.
